Abstract: The Reynolds Risk Score best-fitting model (RRS) estimates 10-year coronary heart disease (CHD) risk by incorporating an expanded number of risk markers, including A1C, systolic blood pressure, C-reactive protein (hsCRP), apolipoproteins, and the interaction of lipoprotein(a) and ApoB. Treatment of type 2 diabetes (T2DM) with the GLP-1 receptor agonist exenatide has been reported to improve A1C, body weight, blood pressure, and lipid profiles; however, evidence regarding the impact of exenatide on other apolipoproteins is limited.